Bioequivalence and Bioavailability Forum 04:17 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

How to demonstrate the bioequivalence of sulodexide [Design Issues]

posted by bjkim97 - Korea / Seoul, 2018-05-30 08:41  - Posting: # 18828
Views: 690

We are planning to development of the sulodexide.

As far as I Know, this product does not have accurate guldelines and design.

So I have reviewed several documents. The FDA and EMEA have identified guidelines for LMWH.

The sulodexide is defined as follows.

Sulodexide is highly purifuled mixture of glycosaminoglycans composed of FMH (Fast Moving Heparin) (80%) and Dermatan sulfate (20%).

I will refer to the FDA enoxaparin recommend guidelines for pharmacodynamic equivalence.

Just one question:
I am not sure if enoxaparin recommendations can be applied to Sulodexide.

I want to hear your opinion. Please give me your opinion

Thanks.

BJ

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,939 posts in 4,040 threads, 1,288 registered users;
online 9 (0 registered, 9 guests [including 7 identified bots]).

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed